Table 4.
Clinical diagnosis after a multidisciplinary team discussion.
| Clinical diagnosis | No. (%) |
|---|---|
| IPF | |
| – High confidence | 8 (21,1) |
| – Low confidence | 2 (5,3) |
| HP | |
| – Subacute | 3 (7,9) |
| – Chronic | 3 (7,9) |
| SR-ILD | 5 (13,2) |
| Possible NSIP/possible IPF | 2 (5,3) |
| Idiopathic NSIP | 2 (5,3) |
| Sarcoidosis | 2 (5,3) |
| Drug induced-ILD | 2 (5,3) |
| Vasculitis (ANCA associated) | 1 (2,6) |
| Scleroderma-associated ILD | 1 (2,6) |
| Organizing pneumonia | 1 (2,6) |
| Histiocytosis X | 1 (2,6) |
| LAM | 1 (2,6) |
| Pulmonary nodular lymphoid hyperplasia | 1 (2,6) |
| Dendriform metaplasia | 1 (2,6) |
| Antisynthetase syndrome | 1 (2,6) |
| No diagnosis | 1 (2,6) |
IPF: idiopathic pulmonary fibrosis; HP: hypersensitivity pneumonitis; SR-ILD: smoking-related interstitial lung disease, including bronchiolitis and RB-ILD; NSIP: non-specific interstitial pneumonitis; ANCA: antineutrophilic antibodies; LAM: lymphangioleiomyomatosis.